### ARTICLE IN PRESS

Progress in Neuro-Psychopharmacology & Biological Psychiatry xxx (2013) xxx-xxx



Contents lists available at SciVerse ScienceDirect

### Progress in Neuro-Psychopharmacology & Biological Psychiatry



journal homepage: www.elsevier.com/locate/pnp

# Q21 Neuronal injury, but not microglia activation, is associated with ketamine-induced Q32 experimental schizophrenic model in mice

Yue Hou, Hongli Zhang, Guanbo Xie, Xinyue Cao, YaNan Zhao, Yang Liu, Zhihao Mao,
Jingyu Yang \*, Chunfu Wu \*

5 Department of Pharmacology, Shenyang Pharmaceutical University, 110016 Shenyang, PR China

#### A R T I C L E I N F O

Article history: 9 Received 9 February 2013 Received in revised form 21 March 2013 10 Accepted 3 April 2013 11 12Available online xxxx 18 16 Keywords: 17 Ketamine 18 Microglia 19Neurons 20 Schizophrenia

#### ABSTRACT

Schizophrenia is a chronic debilitating psychiatric disorder affecting as many as 1% of the population world- 21 wide. Unfortunately, its etiology and pathophysiology are poorly defined. Previous studies have shown that 22 neuronal injury and microglia activation were observed in the schizophrenic patients. The present study 23 aims to evaluate the role of neurons and microglia in ketamine-induced experimental schizophrenic model 24 to further understand its pathophysiology. Firstly, ketamine was used to simulate the behavior abnormalities 25 associated with schizophrenia. The effects of ketamine on mouse locomotor activity, Y-maze task, novel ob- 26 ject recognition, and forced swimming test were studied. The results showed that ketamine (25, 50, and 27 100 mg/kg i.p.) administered acutely or repeatedly (for 7 days) can increase the locomotor number signifi- 28 cantly. In Y-maze task, ketamine (25, 50, and 100 mg/kg) impaired spontaneous alternation after both 29 acute and repeated treatments. In novel object recognition test, acute or chronic ketamine treatment showed 30 no significant effect on mouse exploratory preference behavior. In forced swimming test, repeated treatment 31 of ketamine (100 mg/kg) enhanced the immobility duration. Secondly, immunohistochemical method was 32 used to study the changes of neurons and microglia. The results showed that acute treatment of ketamine 33 (100 mg/kg) had no effect on neurons in the prefrontal cortex or hippocampus (1, 3, 5, and 7 days after 34 the treatment). In contrast, repeated treatment of ketamine caused neuronal impairment in mouse hippo-35 campus (3rd day, 5th day and 7th day after the final administration). The results of immunohistochemistry 36 demonstrated that microglia in the prefrontal cortex and hippocampus were not affected after acute or re- 37 peated administration of ketamine. Finally, the neuronal impairment caused by repeated administration of 38 ketamine was further investigated from the oxidative stress aspects. The results showed that repeated ad- 39 ministration of ketamine increased nitric oxide (NO) and nitric oxide synthase (NOS) in prefrontal cortex, 40 hippocampus and serum, while decreased SOD in hippocampus and serum. In summary, chronic ketamine 41 treatment to mice successfully mimics the core behavioral deficits in schizophrenia. It is demonstrated for 42 the first time that neuronal injury was associated with the chronic ketamine-induced experimental schizo- 43 phrenic model, while microglial cells may play a little role in this model. Oxidative stress may contribute 44 to the significant neuronal injury in mouse brain induced by chronic ketamine treatment. 45

© 2013 Published by Elsevier Inc. 46

48

#### 50 49

52

53

54 55

56

57

58

6

#### 51 **1. Introduction**

Schizophrenia is a chronic debilitating psychiatric disorder affecting as many as 1% of the population worldwide (Reus, 2008). Typical symptoms of schizophrenia can be separated into positive symptoms (e.g., hallucinations, delusions, and thought disorder), negative symptoms (e.g., deficits in social interaction, emotional expression, and motivation), and cognitive dysfunction (e.g., impaired attention/information processing, problem-solving, processing speed, verbal and visual learning,

\* Corresponding authors at: Department of Pharmacology, Shenyang Pharmaceutical University, Wenhua Road 103, Shenyang 110016, PR China. Tel./fax: + 86 24 23843567.

0278-5846/\$ - see front matter © 2013 Published by Elsevier Inc. http://dx.doi.org/10.1016/j.pnpbp.2013.04.006 and memory and working memory) (Nuechterlein et al., 2004; Pearlson, 59 2000). 60

At present, the pathophysiology of schizophrenia is only partially 61 understood and the investigation of it relies on suitable animal models, 62 which simulate core behavioral aspects of human psychosis associated 63 with schizophrenia. For example, amphetamine, used extensively in 64 modeling psychosis, was used quite successfully in bringing forth the 65 concept of dopamine as one of the prominent players in the pathophys-66 iology of schizophrenia (Carlsson et al., 1997). However, it does not induce the negative symptoms of schizophrenia (Sams-Dodd, 1998). In contrast, N-methyl-D-aspartate (NMDA) receptor antagonists, such as ketamine, phencyclidine (PCP), and MK-801 were reported to induce 70 a wider spectrum of behavioral responses that encompass positive, neg-71 ative, and cognitive schizophrenia-like symptoms in healthy human 72

Please cite this article as: Hou Y, et al, Neuronal injury, but not microglia activation, is associated with ketamine-induced experimental schizophrenic model in mice, Prog Neuro-Psychopharmacol Biol Psychiatry (2013), http://dx.doi.org/10.1016/j.pnpbp.2013.04.006

*E-mail addresses:* yangjingyu2006@gmail.com (J. Yang), wucf@syphu.edu.cn (C. Wu).

2

### **ARTICLE IN PRESS**

volunteers (Javitt and Zukin, 1991) and rodents (Chatterjee et al.,
2011). Thus, NMDA receptor antagonist-induced animal models have
become an important tool of choice to study the pathophysiology of
schizophrenia.

As one of the non-competitive NMDA receptor antagonists, keta-77 mine is known for its strong psychotomimetic effects in humans and ro-78 79dents (Krystal et al., 1994). Controlled administration of ketamine in 80 healthy volunteers leads to positive, negative, and cognitive symptoms 81 similar to those observed in schizophrenic patients (Krystal et al., 2003). 82 Subanesthetic ketamine administration also induces behavioral alter-83 ations in animals. Acute administration of ketamine impairs attentional set-shifting in rodents (Kos et al., 2011; Nikiforuk et al., 2010). Both 84 acute and chronic treatments of ketamine can induce hyperlocomotor 85 86 response and reduce the transfer-latency time in passive avoidance test (Chatterjee et al., 2011). In a recent study, an increased stereotyped 87 activity and grooming with a decreased rearing as compared to controls 88 were observed in mice treated subchronically with subanesthetic doses 89 of ketamine (Rao et al., 2012). 90

A variety of lines of converging evidence implicates that neuronal 91 injury is associated with schizophrenia. For example, a decrease in **05**92 basilar dendrites of pyramidal cells has been found in schizophrenic 93 medial prefrontal cortex (Broadbelt et al., 2002). It was reported 94 95 that the schizophrenia subjects had 40% fewer total ring intersections per neuron than comparison subjects and a smaller basilar dendritic 96 field size was evident in proximal and distal branches, which indicat-97 ed that abnormal dendritic outgrowth or maintenance contributes to 98 reduced neuropil and prefrontal connectivity in schizophrenia (Black 99 100 et al., 2004). Glantz and Lewis have reported a decreased dendritic spine density on prefrontal cortical pyramidal neurons in schizophre-101 nia (Glantz and Lewis, 2000). 102

In recent years, microglial cells have shown to be involved in 103 104many CNS illnesses. Monji et al. have proposed the microglia hypoth-105esis of schizophrenia (Monji et al., 2009). It was found that the number of activated microglia was higher in schizophrenic brains than in 106 control brains (Wierzba-Bobrowicz et al., 2005). A quantitative posi-107 tron emission tomography study has shown microglia activation in 108 recent-onset schizophrenia (van Berckel et al., 2008). Postmortem 109110 study reveals the increased microglia densities in schizophrenic patients who had committed suicide (Steiner et al., 2006). However, in-111 consistent role of microglia in schizophrenia has been also observed. 112 A postmortem study has revealed that microglia show no statistically 113 significant differences between the patients with schizophrenia and 114 the control patients (Arnold et al., 1998). 115

Although ketamine has been used to mimic the schizophrenialike symptoms in rodents, the characteristic of this model is still not well-defined. Moreover, whether or not the neurons or microglia is involved in ketamine-induced schizophrenia-like symptoms is not clear. Therefore, in the present study, we attempted to evaluate the role of neurons and microglia in ketamine-induced experimental schizophrenic model.

#### 123 2. Materials and methods

#### 124 2.1. Animals

Male Swiss-Kunming mice with body weight of 25-30 g were 125126supplied by the Experimental Animal Center of Shenyang Pharmaceutical University. The animals were housed under standard conditions 127with a 12-12 h light-dark cycle (lights on 7 h) and free access to food 128 and water. The mice were used for the behavioral experiments after 129they had been adapted to laboratory conditions for at least 5 days. 130All animal use procedures were in accordance with the Regulations 131 of Experimental Animal Administration issued by the State Commit-132tee of Science and Technology of the People's Republic of China. The 133 experiments were carried out under the approval of the Committee 134 135 of Experimental Animal Administration of the University.

#### 2.2. Drugs

Ketamine hydrochloride (Fujian Gutian Medicine Co., Ltd.) was 137 dissolved in 0.9% saline and i.p. in a volume of 0.1 ml/10 g body 138 weight. Controls received 0.9% saline alone. 139

#### 2.3. Experimental protocol

The animals were randomly divided into control group and ketamine groups (25, 50, 100 mg/kg, i.p.). In the acute experiment, mice in the control or ketamine groups were treated with 0.9% saline or ketamine only once. In the chronic experiment, mice in the control twe treated with 0.9% saline or ketamine once twe treated with 0.9% saline or ketamine once twe treated with 0.9% saline or ketamine once two saline or ketamine groups were treated with 0.9% saline or two saline or ketamine once two saline or two saline or ketamine once two saline once two saline once two saline once two s

#### 2.4. Behavioral assessment

#### 2.4.1. Locomotor activity

The locomotor activity was tested as described earlier (Hou et al., 149 2006). Mice were randomly assigned to each group. After the initial 150 10-min habituation process, the mice were treated with 0.9% saline 151 or ketamine and then the locomotor activity of the mice was measured in a locomotor monitoring cage ( $25 \times 25 \times 25$  cm, Shanghai 153 Mobiledatum Information Technology Co., Ltd., China) for 60 min. The 154 experimenter was blind to the medication status. The animal's movement was recorded and analyzed using a computerized video-tracking 156 system (Ethovision@ 8.0, Noldus Information Technology, Wageningen, 157 Netherlands). 158

#### 2.4.2. Forced swimming test

The forced swimming test was performed as previously reported 160 (Noda et al., 1997, 2000). In brief, mice were placed individually in 161 glass cylinders (20 cm height, 12 cm diameter) containing 10 cm 162 depth of water at 25 °C. After 5 min, the animals were removed from 163 water, dried and returned back to their home cages. They were again 164 placed in the cylinder 24 h later and the total duration of immobility 165 was measured for 3 min. Mice which were floating motionless were 166 considered to be immobile. The experimenter was blind to the medica-167 tion status. The animal's movement was recorded and analyzed using a 168 computerized video-tracking system (Ethovision@8.0, Noldus Information 169 tion Technology, Wageningen, Netherlands).

#### 2.4.3. Y-maze task

Spontaneous alternation was assessed in the Y-maze task (Bild et 172 al., 2013; Józwiak et al., 2006). Each arm of the maze was 38 cm long, 173 12 cm high and 5 cm wide, and converged to an equal angle. Each 174 mouse was placed at the end of one arm and allowed to move freely 175 through the maze during an 8-min session. The total number of arm 176 entries and alternation (defined as consecutive entries into all three 177 arms without repetitions) was scored. Total number of arm entries 178 was collected cumulatively over 8 min. The percent alternation was 179 calculated as the ratio of actual to possible alternations (defined as 180 the total number of arm entries -2) × 100. In the acute experiment, 181 mice were injected once with 0.9% saline or ketamine 30 min before 182 the test session in the Y-maze. In the chronic experiment, the Y-maze 183 task was done 30 min after the final injection of 0.9% saline or ketamine. 184 The experimenter was blind to the medication status. 185

#### 2.4.4. Novel object recognition (NOR) test

NOR test was performed as previously reported (Hashimoto et al., 187 2005; Kunitachi et al., 2009). The apparatus for this task consisted of a 188 black open field box ( $50 \times 50 \times 50$  cm). The procedure for the novel 189 object recognition test consisted of different sessions: habituation, 190 training and retention. Before the test, mice were habituated in the 191 box for 3 days. During a training session, two objects (various objects 192 differing in shape and color but similar in size) were placed in the box 193

Please cite this article as: Hou Y, et al, Neuronal injury, but not microglia activation, is associated with ketamine-induced experimental

schizophrenic model in mice, Prog Neuro-Psychopharmacol Biol Psychiatry (2013), http://dx.doi.org/10.1016/j.pnpbp.2013.04.006

136

140

147

148

159

171

186

Download English Version:

## https://daneshyari.com/en/article/5844801

Download Persian Version:

https://daneshyari.com/article/5844801

Daneshyari.com